1 option
CADTH Canadian drug expert committee recommendation : indication : glaucoma and ocular hypertension. Latanoprost (Monoprost -- Laboratoires Thea) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Cost effectiveness.
- Physical Description:
- 1 online resource (7 pages) : illustrations
- Edition:
- First edition.
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018.
- Summary:
- The CADTH Canadian Drug Expert Committee (CDEC) recommends that preservative-free latanoprost 50 μg/mL ophthalmic solution (Monoprost) be reimbursed for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension, if the following condition is met: The drug plan cost of treatment with Monoprost should not exceed the drug plan cost of treatment with the least costly prostaglandin analogue (PGA).
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.